485 results about "Weight loss" patented technology

The invention relates to the technical field of rehabilitation medicine, in particular to a body carving slimming method for fat metabolism based on bioelectricity feedback and acupoint stimulation. The invention provides a body carving slimming method based on bioelectricity feedback and acupoint stimulation. The body carving slimming method comprises the four steps of obtaining, processing, acupoint stimulation and outputting. Bioelectricity signals and weight data of body parts of a user are collected through a bioelectricity and weight detection device. The muscle activity state and fat distribution are analyzed, a posture improvement value is calculated, and a personalized body carving training scheme is generated. In an acupoint stimulation link, electrical stimulation is performed on a specific acupoint according to the scheme, bioelectricity feedback is monitored in real time, and stimulation parameters are dynamically adjusted. And generating a personalized report containing the posture change and the training effect evaluation, and providing suggestions to the user. According to the method, the effect, safety and individuation are remarkably improved, and a new direction is opened up for development of the body carving and slimming field.

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention discloses a movement detection and feedback intervention system for obese patients, and relates to the technical field of movement intervention for obese patients, the system comprises a data acquisition module, a personalized movement scheme generation module, a movement monitoring module and an interaction module; according to the method, artificial intelligence and big data analysis technologies are deeply fused, multivariate data of a patient is comprehensively and accurately collected, a personalized exercise scheme meeting individual requirements can be generated, the pertinence of the exercise scheme is improved, and during exercise monitoring, the multi-modal data fusion technology is applied, so that the accuracy of exercise monitoring is improved. Various physiological parameters and exercise environment data of a patient are collected in an omnibearing mode, the state of the patient is accurately controlled in real time, once monitoring data deviates from a preset target, parameters such as exercise items, strength, time and frequency in an exercise scheme can be rapidly and dynamically adjusted according to a real-time deviation correction algorithm, the safety of the exercise process is practically guaranteed, and the exercise efficiency is improved. The goal of losing weight is effectively promoted.

Methods for enhancing weight loss, or preventing or treating obesity or other conditions related thereto, such as diabetes, involve administering a GLP-1 agonist together with, or prior to, administering a mitochondrial uncoupler. Use of the uncoupler increases weight loss and enhances treatment of obesity and obesity-related medical conditions, such as by preventing weight regain after cessation of administration of the GLP-1 agonist.

The invention provides novel compounds which are peptide hormone analogues, and which are useful in treating disorders such as diabetes and obesity. The compounds of the general sequence recited in the specification possess a tailored profile with regards to potency properties at the GIP receptor. With regard to in vivo properties, administration of example peptides of the invention have been shown, in animal models, to result in increased weight loss. Preferred compounds achieve this without reducing food intake significantly.

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.

The invention discloses pericarpium citri reticulatae compound protein powder as well as a preparation method and application thereof. The protein powder takes pericarpium citri reticulatae extract microcapsules, seville orange flower extract microcapsules, soybean protein isolate powder, polydextrose, resistant dextrin, soybean peptide powder, tremella powder and the like as main components, and further comprises edible salt, edible essence, a nutrition enhancer, a sweetening agent and an anti-caking agent. The preparation method comprises the steps of raw material weighing, premixing, high-speed shearing and mixing and the like. Active components of the dried orange peel and seville orange flower extract are extracted through an ultrasonic-assisted ethanol extraction method, and sodium alginate and chitosan are adopted for microencapsulation treatment, so that the stability and solubility of the dried orange peel and seville orange flower extract are improved. The compound protein powder disclosed by the invention has the functions of maintaining muscle mass and relieving symptoms such as nausea and abdominal distension in a weight loss process, has good storage stability and safety, and is suitable for being taken for a long time.

A process for removing water from a functional ingredient composition containing 10% by weight or more of water, which process does not require the input of thermal energy. 【Solution means】The amount of water in the resulting dehydrated product is 33% or less of the starting amount of water in the functional ingredient, and the method results in a dehydrated product having a weight loss of 2% or less based on the total weight of the starting components.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

The invention provides a weight-losing formula containing medicinal and edible components, and belongs to the technical field of medicines. The weight-losing formula comprises the following components in parts by weight: 35-50 parts of oat kernels, 10-12 parts of poria cocos, 20-30 parts of coix seeds, 5-8 parts of radix ophiopogonis, 10-15 parts of codonopsis pilosula, 5-8 parts of Chinese wolfberry fruits, 1-2 parts of dried orange peel, 10-15 parts of Chinese yams, 8-12 parts of haws, 10-16 parts of astragalus membranaceus, 3-5 parts of purple perilla, 15-20 parts of soybean protein isolate, 10-15 parts of red beans and 10-15 parts of fructus cannabis protein peptides. According to the weight-losing formula disclosed by the invention, natural medicinal material synergy is taken as a core, 14 components are compounded according to a specific ratio, a synergistic and complementary effect can be realized, and a large number of experiments prove that the weight-losing formula provided by the invention has the effects of comprehensively improving and controlling the weight, reducing the fat coefficient, improving lipid metabolism and preventing weight rebound. Moreover, the food is better in eating experience and safety, and suitable for long-term eating.

Described herein is a composition comprising at least one of a lotus leaf extract (LLE), a chrysanthemum extract (CME), and a Pu'er tea extract (PTE), the composition having an agonistic effect on the glucagon-like peptide-1 receptor (GLP-1R). In addition, compositions comprising a mixture of LLE, CME, and PTE are described herein. Also described are methods of using the described compositions, e.g., for supporting weight loss efforts in a subject in need thereof.

The present invention provides compositions comprising one or more ACAT inhibitors and one or more GLP-1 receptor agonists (GLP-1 RAs). The combination therapy reduces side effects associated with high-dose GLP-1 RA monotherapy and provides durable management of weight loss by suppressing rebound of body weight, blood glucose, and cholesterol levels after treatment.

The invention belongs to the field of intestinal microbiology, and discloses a novel ackermania muciniphila capable of improving obesity and glycolipid metabolism, and the ackermania muciniphila strains are Akk-101 and AMY001. The preservation number of the Akk-101 is CGMCC (China General Microbiological Culture Collection Center) No. 40786, and the preservation number of the AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have acid-base tolerance and colonization ability superior to those of the standard strains, and have the effects of more effectively inhibiting lipid accumulation of liver cells, reducing fat deposition in nematode bodies, losing weight and improving glycolipid metabolism. Therefore, related products can be effectively developed based on the strain.

Disclosed herein include methods, compositions, and kits suitable for use in preventing or relieving side effects associated with the administration of a weight loss medication. The method can comprise administering to a subject under a weight loss treatment a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant).

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The invention is an AI-powered fitness and health management system providing personalized, dynamic recommendations tailored to user-specific goals such as weight loss, muscle gain, and diabetes management. Leveraging Artificial Neural Networks (ANN), Decision Tree algorithms (J48), and Convolutional Neural Networks (CNN), the system analyzes user inputs, including voice commands, wearable device data, blood glucose readings, and food scans, to deliver real-time, adaptive meal and workout plans. Voice activation, initiated with the command “Run Fitzy”, enables hands-free logging of meals, workouts, and health metrics. Computer vision technology scans food labels and meal images, extracting nutritional data and automatically integrating it into the user's profile. The system dynamically adjusts remaining daily meals and activities to meet caloric, fitness, and glucose targets. Social networking features include geo-tagging, fitness challenges, and monetizable content sharing. Built on a secure, scalable cloud infrastructure, the platform integrates e-commerce functionality and ensures compliance with data protection standards.

The invention relates to the technical field of rice product processing, in particular to high-toughness nutritional rice noodles as well as a preparation method and application thereof. The novel food raw material peach gum and other raw materials are scientifically proportioned, and a twin-screw extrusion technology is combined to generate the high-toughness rice noodles. By optimizing the raw material ratio and process parameters, the toughness, nutritional value and functionality of the rice noodles are remarkably improved; functional dietary fibers are introduced into the formula of the rice noodles, so that the starch digestion rate is regulated and controlled, and the intestinal function is improved. The high-toughness nutritional rice noodles developed by the invention show a relatively balanced characteristic in texture characteristic detection, have unique advantages and potentials in the aspects of controlling the starch digestion rate and improving the intestinal function, can effectively maintain the nutrition and taste of food materials, are compound rice noodles with the characteristics of high toughness, nutrient enrichment and chronic disease adaptation, and have a broad market prospect. The food is suitable for diabetics and weight-losing people to eat.

The invention relates to a pterostilbene compound, a pharmaceutical composition and application of the pterostilbene compound in preparation of anti-inflammatory drugs. The compound shown in the formula (I) or the pharmaceutically acceptable salt thereof provided by the invention has relatively high stability and high bioavailability, can effectively improve symptoms such as colon shortening, diarrhea, hematochezia and weight loss caused by DSS-induced mouse colitis, has a remarkable inhibition effect on intestinal inflammation, and can be used for preparing anti-inflammatory drugs. # imgabs0 #

The invention belongs to the related technical field of pet prescription food products, and particularly relates to a prescription food for pet dogs with acute intestinal inflammation and a preparation method of the prescription food, the prescription food comprises various components such as rice, barley, chicken powder and corn protein powder, and probiotics are self-made and comprise bifidobacterium, lactobacillus acidophilus and lactobacillus casei. The preparation method comprises the steps of quantitative raw material weighing, auxiliary agent grinding, constant-temperature accurate grinding, adding of specific components for accurate grinding again, heat preservation, deodorization and degassing, drop casting forming, cooling, packaging, sealed storage and the like. Compared with the prior art, the prescription food is high in safety, and feeding tests of healthy dogs have no abnormity; clinical cases show that the leucocyte number and the inflammatory factor content of sick dogs can be reduced; the intestinal barrier can be repaired, so that the intestinal mucosa repair is accelerated; intestinal flora can be improved, and the content of short-chain fatty acid in excrement is increased; the nutrition state can be maintained, and the weight loss range of sick dogs is reduced.

A system is disclosed that monitors participants in health-related programs, such as weight loss or exercise programs, and that provides automated, personalized health coaching to the program participants. The system includes breath analysis devices that are used by the program participants to generate ketone measurements, and includes a mobile application that runs on mobile devices of the participants and communicates with corresponding breath analysis devices. The system operates generally by monitoring ketone levels (such as acetone levels) and other attributes of the participants and by making personalized, machine-generated changes or updates to such programs to maintain program effectiveness and engagement. In some embodiments the system uses artificial intelligence to classify and coach the participants.

The invention discloses application of a traditional Chinese medicine composition in preparation of a product for resisting colon cancer and tumor hemagglutinin, and relates to the technical field of biology. The traditional Chinese medicine composition is prepared from the following components: 5-150 parts of American ginseng, 5-160 parts of lucid ganoderma, 1-90 parts of fermented cordyceps sinensis powder and 5-90 parts of roses. Or 5-150 parts of American ginseng, 5-160 parts of lucid ganoderma, 1-60 parts of cordyceps sinensis and 5-90 parts of rose. The traditional Chinese medicine composition provided by the invention can improve weight loss related to tumors, inhibit tumor growth, recover food intake, improve the athletic ability of a patient, relieve muscle and fat atrophy, inhibit spleen swelling, improve anemia and peripheral inflammation, and effectively relieve cancer-related fatigue caused by colon cancer, so that the traditional Chinese medicine composition provided by the invention has the advantages that the effect is obvious; the traditional Chinese medicine composition can be used for effectively treating colon cancer and malignant fluid, and has a wide application prospect in preparation of products for treating colon cancer and malignant fluid.

The invention discloses an application of ganoderma lucidum spore oil in preparation of a medicine or health food for improving sarcopenia. Ganoderma lucidum spore oil can effectively improve weight loss and muscle hypofunction induced by glucocorticoid, and improve the holding power and exercise tolerance level of the body; meanwhile, the skeletal muscle mass and the muscle fiber cross sectional area can be increased, and the skeletal muscle tissue morphological structure is improved; in addition, the ganoderma lucidum spore oil can improve the oxidation resistance of the body and skeletal muscle and reduce the oxidative stress level, so that the skeletal muscle injury related to aging is relieved on the whole. Therefore, the ganoderma lucidum spore oil has a definite application value in the aspect of improving the skeletal muscle function.

The invention discloses a traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-50 parts of sweet wormwood, 3-30 parts of scutellaria baicalensis, 5-50 parts of dandelion, 4-60 parts of platycodon grandiflorum, 5-50 parts of fructus aurantii, 3-80 parts of rhizoma pinelliae preparata, 3-70 parts of fructus amomi, 10-80 parts of stir-fried Chinese yam, 5-80 parts of poria cocos and 3-100 parts of raw coix seeds. The traditional Chinese medicine composition for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes is simple in formula, proper in compatibility and mild in medicine property, is used for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes, is used for improving liver fatty degeneration and inflammation, blood uric acid, blood fat, blood sugar and blood pressure, assisting weight loss and the like, and is safe to use and remarkable in curative effect.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

The invention relates to technical development and application of new special medical food on the basis of a new food raw material framework, and belongs to the technical field of special medical purpose formula food (FSMP). According to the series of foods, new food raw materials (euglena, haematococcus pluvialis and ampelopsis grossedentata leaves) are taken as cores, medicinal and edible components (lotus leaves, haws and mulberry leaves) and marine active substances (fucoidan polysaccharides and chitin) are combined, functional factors are extracted through a prehydrolysis SBE technology and a biological enzymolysis technology, and the bioavailability is improved by adopting a nano-carrier technology. The product comprises a total nutrient base material (20-30% of protein and 15-25% of dietary fiber), functional components (10-15% of a new food raw material extract and 8-12% of a traditional Chinese medicine extract) and a metabolism regulator (conjugated linoleic acid and L-carnitine). Clinical tests show that after an obese patient takes 400 kcal of the replacement meal every day, the weight of the obese patient is reduced by 10.2 kg on average (4.8 kg of a control group) 12 weeks later, and the body fat rate is reduced by 16.3%. The product supports line iteration (such as powder, tablets and liquid food) through modular formula design, and fills the application blank of new food raw materials in special medical food.

The invention relates to the field of medicine, and discloses a heterocyclic compound with a GLP-1 receptor agonist effect and application of the heterocyclic compound, the heterocyclic compound is a compound with a structure shown in a formula (I), or an isomer, an isotope labeled compound, a prodrug, or pharmaceutically acceptable salt, ester, hydrate or solvate of the compound. The obvious treatment effect is realized in the aspect of reducing blood sugar or reducing weight.

A weight loss supplement composition is disclosed. The composition comprises a first pre-defined amount of dairy product such that the dairy product is a heavy and lactose-free whipping cream; an effective amount of sugar-free flavoring extract; and a second pre-defined amount of isolate whey protein; wherein the first pre-defined amount of the dairy product, the effective amount of the sugar-free flavoring extract, the second pre-defined amount of the isolate whey protein are mixed to a desired consistency for preparing a weight loss supplement.

The invention belongs to the technical field of biology, and particularly relates to a colipase inhibitory peptide and application thereof. The colipase inhibitory peptide has colipase inhibitory activity, can significantly reduce fat absorption by inhibiting the activity of colipase, achieves the effects of losing weight and reducing blood fat, is safe and free of toxic and side effects, has good stability and low blood absorptivity, and is beneficial for polypeptide to better inhibit the colipase to play a role in digestive tracts.

The present invention provides a strain of the genus Alistipes as well as a pharmaceutical composition comprising the strain or an extract of the strain. The strain and the pharmaceutical composition disclosed by the invention can be used for remarkably relieving such symptoms as weight loss, shortened colon length, inflammatory factor release and the like of an enteritis object, and do not have toxic or side effects. Therefore, the another mycobacterium strain or the active extract of the another mycobacterium strain can be used for preparing pharmaceutical compositions and fermented foods for relieving enteritis, and has a very wide application prospect.

The present application relates to the field of medicine, and specifically to a GLP-1 analog fusion protein and its application. The GLP-1 analog fusion protein is obtained by fusing GLP-1 to the N-terminus of the IgG4 heavy chain constant region and the light chain constant region. The results of the study showed that the GLP-1 analog fusion protein of the present application has a significant effect on reducing the weight of mice. The volume and weight of the mouse liver decreased, and the NAS score and hepatic steatosis were significantly improved. Therefore, the present invention can be applied to drugs or products for weight loss or the treatment of fatty liver.